Stemline Therapeutics Inc (NASDAQ:STML) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,811,227 shares, an increase of 31.1% from the January 15th total of 2,144,312 shares. Approximately 7.6% of the shares of the stock are sold short. Based on an average daily volume of 1,224,535 shares, the short-interest ratio is presently 2.3 days.
In other news, COO Kenneth Hoberman sold 26,296 shares of Stemline Therapeutics stock in a transaction on Monday, November 26th. The stock was sold at an average price of $11.85, for a total value of $311,607.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 14.80% of the company’s stock.
Get Stemline Therapeutics alerts:
A number of hedge funds have recently modified their holdings of STML. Great West Life Assurance Co. Can bought a new stake in Stemline Therapeutics during the 4th quarter worth $47,000. Metropolitan Life Insurance Co. NY grew its position in Stemline Therapeutics by 327.0% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,523 shares of the biopharmaceutical company’s stock worth $81,000 after acquiring an additional 6,527 shares during the last quarter. Bank of America Corp DE grew its position in Stemline Therapeutics by 56.8% during the 4th quarter. Bank of America Corp DE now owns 10,669 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 3,866 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in Stemline Therapeutics during the 4th quarter worth $108,000. Finally, Hikari Power Ltd bought a new stake in Stemline Therapeutics during the 4th quarter worth $144,000. Institutional investors and hedge funds own 65.39% of the company’s stock.
Several equities analysts have recently issued reports on STML shares. Piper Jaffray Companies reiterated an “overweight” rating on shares of Stemline Therapeutics in a research note on Wednesday, February 6th. BidaskClub upgraded Stemline Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 24th. HC Wainwright set a $38.00 price target on Stemline Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 21st. Roth Capital set a $33.00 price target on Stemline Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 14th. Finally, ValuEngine upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 23rd. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Stemline Therapeutics currently has a consensus rating of “Buy” and an average target price of $25.40.
Shares of STML stock opened at $11.11 on Friday. The firm has a market cap of $362.85 million, a P/E ratio of -3.78 and a beta of 1.12. Stemline Therapeutics has a twelve month low of $7.82 and a twelve month high of $20.55.
TRADEMARK VIOLATION WARNING: “Stemline Therapeutics Inc (STML) Short Interest Up 31.1% in January” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at www.tickerreport.com/banking-finance/4152714/stemline-therapeutics-inc-stml-short-interest-up-31-1-in-january.html.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Recommended Story: How to Use a Moving Average for Trading